Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Participants in Asia With Early Triple-Negative Breast Cancer An Updated Subgroup Analysis of the KEYNOTE-522 Randomized Clinical Trial

Study limitation reported by the research below: “Publication date is August 2026; as of today (August 26, 2026), this is a very recent publication and full-text data may not yet be widely indexed.”